MG-262 is a potent proteasome inhibitor primarily used in research settings to study cellular processes involving protein degradation. It is widely applied in cancer research due to its ability to induce apoptosis in tumor cells by blocking the proteasome pathway. This compound helps investigate the role of ubiquitin-proteasome system dysfunction in diseases like multiple myeloma and other malignancies. It is also used to explore mechanisms of drug resistance and to evaluate combination therapies with other anticancer agents. Due to its high specificity and potency, MG-262 serves as a valuable tool in biochemical assays and target validation studies in molecular pharmacology.